Theravance Biopharma, Inc. Restricted Cash and Cash Equivalents
Theravance Biopharma, Inc. (TBPH) had Restricted Cash and Cash Equivalents of $833.00 thousand as of 2018-03-31, per its 10-Q filed 2018-05-09.
Discontinued › Balance Sheet › Assets
us-gaap:RestrictedCashAndCashEquivalents · last filed 2018-05-09
- 2018-03-31: Restricted Cash and Cash Equivalents $833.00K.
- 2017-03-31: Restricted Cash and Cash Equivalents $833.00K.
- 2016-12-31: Restricted Cash and Cash Equivalents $800.00K.
- 2015-12-31: Restricted Cash and Cash Equivalents $800.00K.
| Period end | Restricted Cash and Cash Equivalents |
|---|---|
| 2018-03-31 | $833.00K 10-Q · filed 2018-05-09 |
| 2017-03-31 | $833.00K 10-Q · filed 2018-05-09 |
| 2016-12-31 | $800.00K 10-K · filed 2017-03-01 |
| 2015-12-31 | $800.00K 10-K · filed 2017-03-01 |
| 2014-12-31 | $800.00K 10-K · filed 2015-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |